Anthropometric factors and risk of molecular breast cancer subtypes among postmenopausal Norwegian women

International Journal of Cancer

Volumn 135, Issue 11, 2014, Pages 2678-2686

  Horn, Julie ^a,b   Alsaker, Mirjam D K ^a,c   Opdahl, Signe ^a   Engstrm, Monica J ^d   Tretli, Steinar ^e   Haugen, Olav A ^d   Bofin, Anna M ^d   Vatten, Lars J ^a   Asvold, Bjrn Olav ^a,c  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b Department of Gynecology and Obstetrics Levanger Hospital Nord Trndelag Hospital Trust   (Norway)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^d NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^e CANCER REGISTRY OF NORWAY   (Norway)

Author keywords

BMI; Breast cancer; Height; Molecular subtype

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; BODY HEIGHT; BODY MASS; BREAST CANCER; CANCER INCIDENCE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MENARCHE; NORWEGIAN (PEOPLE); PHENOTYPE; POSTMENOPAUSE; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTOR; RURAL POPULATION; TISSUE MICROARRAY; URBAN POPULATION; BREAST NEOPLASMS; CANCER STAGING; CLASSIFICATION; ENZYME IMMUNOASSAY; EPIDEMIOLOGY; FOLLOW UP; METABOLISM; MIDDLE AGED; NORWAY; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY;

ADULT; BODY HEIGHT; BODY MASS INDEX; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM STAGING; NORWAY; POSTMENOPAUSE; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84921634177     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28912     Document Type: Article

References (52)

1. Amadou A, Hainaut P, Romieu I. Role of obesity in the risk of breast cancer: lessons from anthropometry. J Oncol 2013;2013:906495.
2. Friedenreich CM. Review of anthropometric factors and breast cancer risk. Eur J Cancer Prevention 2001;10:15-32.
3. Green J, Cairns BJ, Casabonne D, et al.; Million Women Study c. Height and cancer incidence in the Million Women Study: prospective cohort, and meta-analysis of prospective studies of height and total cancer risk. Lancet Oncol 2011;12:785-94.
4. Renehan AG, Tyson M, Egger M, et al. Bodymass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569-78.
5. Suzuki R, Orsini N, Saji S, et al. Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status-a meta-analysis. Int J Cancer 2009;124:698-712.
6. Bao PP, Shu XO, Gao YT, et al. Association of hormone-related characteristics and breast cancer risk by estrogen receptor/progesterone receptor status in the shanghai breast cancer study. Am J Epidemiol 2011;174:661-71.
7. Canchola AJ, Anton-Culver H, Bernstein L, et al. Body size and the risk of postmenopausal breast cancer subtypes in the California Teachers Study cohort. Cancer Causes Control 2012.
8. Ritte R, Lukanova A, Berrino F, et al. Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study. Breast Cancer Res 2012;14:R76.
9. Goldhirsch A, Winer EP, Coates AS, et al.; Panel m. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013;24:2206-23.
10. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-52.
11. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98: 10869-74.
12. Millikan RC, Newman B, Tse CK, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008;109:123-39.
13. Tamimi RM, Colditz GA, Hazra A, et al. Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer. Breast Cancer Res Treat 2012;131:159-67.
14. Phipps AI, Buist DS, Malone KE, et al. Breast density, body mass index, and risk of tumor marker-defined subtypes of breast cancer. Ann Epidemiol 2012;22:340-8.
15. Phipps AI, Chlebowski RT, Prentice R, et al. Body size, physical activity, and risk of triplenegative and estrogen receptor-positive breast cancer. Cancer Epidemiol Biomarkers Prev 2011; 20:454-63.
16. Phipps AI, Malone KE, Porter PL, et al. Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2008;17:2078-86.
17. Yang XR, Sherman ME, Rimm DL, et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 2007;16:439-43.
18. Amadou A, Ferrari P, Muwonge R, et al. Overweight, obesity and risk of premenopausal breast cancer according to ethnicity: a systematic review and dose-response meta-analysis. Obesity Rev 2013;14:665-78.
19. Huang Z, Hankinson SE, Colditz GA, et al. Dual effects of weight and weight gain on breast cancer risk. JAMA 1997;278:1407-11.
20. Lahmann PH, Hoffmann K, Allen N, et al. Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC). Int J cancer 2004;111:762-71.
21. van den Brandt PA, Spiegelman D, Yaun SS, et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 2000;152:514-27.
22. Tretli S. Height and weight in relation to breast cancer morbidity and mortality. A prospective study of 570,000 women in Norway. Int J cancer 1989;44:23-30.
23. Kvale G, Heuch I, Eide GE. A prospective study of reproductive factors and breast cancer. I. Parity. Am J Epidemiol 1987;126:831-41.
24. Larsen IK, Smastuen M, Johannesen TB, et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer 2009;45: 1218-31.
25. Engstrom MJ, Opdahl S, Hagen AI, et al. Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. Breast Cancer Res Treat 2013;140:463-73.
26. Tavassoli F, Devilee P. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press, 2003.
27. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
28. Lunn M, McNeil D. Applying Cox regression to competing risks. Biometrics 1995;51:524-32.
29. Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009;101:736-50.
30. Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008;14:1368-76.
31. Spencer EA, Appleby PN, Davey GK, et al. Validity of self-reported height and weight in 4808 EPIC-Oxford participants. Public Health Nutr 2002;5:561-5.
32. Bergsj P. Comments on the use of oestrogens 1979-83. In: Øydvin K, ed. Drug Consumption in Norwayed. Oslo: Norsk medisinaldepot, 1984. 114-5.
33. Hofvind S, Sakshaug S, Ursin G, et al. Breast cancer incidence trends in Norway-explained by hormone therapy or mammographic screening? Int J Cancer 2012;130:2930-8.
34. Topo P, Koster A, Holte A, et al. Trends in the use of climacteric and postclimacteric hormones in Nordic countries. Maturitas 1995;22:89-95.
35. Morimoto LM, White E, Chen Z, et al. Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control 2002;13:741-51.
36. Alsaker MD, Janszky I, Opdahl S, et al. Weight change in adulthood and risk of postmenopausal breast cancer: the HUNT study of Norway. Br J Cancer 2013;109:1310-7.
37. Ritte R, Lukanova A, Tjonneland A, et al. Height, age at menarche and risk of hormone receptorpositive and-negative breast cancer: a cohort study. Int J Cancer 2013;132:2619-29.
38. Iwasaki M, Otani T, Inoue M, et al.; Japan Public Health Center-Based Prospective Study G. Body size and risk for breast cancer in relation to estrogen and progesterone receptor status in Japan. Ann Epidemiol 2007;17:304-12.
39. Fagherazzi G, Vilier A, Boutron-Ruault MC, et al. Height, sitting height, and leg length in relation with breast cancer risk in the E3N cohort. Cancer Epidemiol Biomarkers Prev 2012;21:1171-5.
40. Marmot M, Atinmo T, Byers T, et al. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. Washington, DC: World Cancer Research Fund/American Institute for Cancer Res, 2007.
41. Lawlor DA, Okasha M, Gunnell D, et al. Associations of adult measures of childhood growth with breast cancer: findings from the British Women's Heart and Health Study. Br J cancer 2003;89:81-7.
42. John EM, Phipps AI, Sangaramoorthy M. Body size, modifying factors, and postmenopausal breast cancer risk in a multiethnic population: the San Francisco Bay Area Breast Cancer Study. SpringerPlus 2013;2:239.
43. Kawai M, Kakugawa Y, Nishino Y, et al. Anthropometric factors, physical activity, and breast cancer risk in relation to hormone receptor and menopausal status in Japanese women: a case-control study. Cancer Causes Control 2013;24: 1033-44.
44. Krishnan K, Bassett JK, MacInnis RJ, et al. Associations between weight in early adulthood, change in weight, and breast cancer risk in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2013;22:1409-16.
45. Trivers KF, Lund MJ, Porter PL, et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 2009;20: 1071-82.
46. Pierobon M, Frankenfeld CL. Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat 2013;137:307-14.
47. Bernstein L. Epidemiology of endocrine-related risk factors for breast cancer. J Mammary Gland Biol Neoplasia 2002;7:3-15.
48. James RE, Lukanova A, Dossus L, et al. Postmenopausal serum sex steroids and risk of hormone receptor-positive and-negative breast cancer: a nested case-control study. Cancer Prevention Res 2011;4:1626-35.
49. Patel SM, Ratcliffe SJ, Reilly MP, et al. Higher serum testosterone concentration in older women is associated with insulin resistance, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2009;94:4776-84.
50. Key TJ, Appleby PN, Reeves GK, et al. Insulinlike growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol 2010;11:530-42.
51. Gunter MJ, Hoover DR, Yu H, et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2009;101:48-60.
52. Belardi V, Gallagher EJ, Novosyadlyy R, et al. Insulin and IGFs in obesity-related breast cancer. J Mammary Gland Biol Neoplasia 2013;18:277-89.